Trandolapril NDC 63629-8003

NDC codes

FDA NDC Directory

Product NDC (as listed)63629-8003Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63629-8003Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63629-8003-1	63629800301	30 TABLET in 1 BOTTLE (63629-8003-1)Marketed from May 2, 2019
63629-8003-2	63629800302	90 TABLET in 1 BOTTLE (63629-8003-2)Marketed from Feb 9, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Trandolapril
Generic name (nonproprietary): trandolapril
Active ingredients: Trandolapril — 2 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077522
Marketing start: Jun 11, 2007
Listing expires: Dec 31, 2026
Other FDA classes: Angiotensin-converting Enzyme Inhibitors (Mechanism)
Identifiers: Product ID 63629-8003_6393820e-daaa-41b2-b2cb-5fe6c433a854SPL ID 6393820e-daaa-41b2-b2cb-5fe6c433a854SPL set ID 514f53e6-ff6b-4d02-9db9-2575b15aa5f0RxCUI 199351UNII 1T0N3G9CRC
Pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463629800301 followed by a unit qualifier and the quantity

Package 63629-8003-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 5, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

INDICATIONS AND USAGE Hypertension Trandolapril tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principal…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077522

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077522
Product	Strength	Form · route	Labeler	Product NDC
Trandolapril	Trandolapril 1 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	68180-566
Trandolapril	Trandolapril 2 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	68180-567
Trandolapril	Trandolapril 4 mg/1	TabletOral	Lupin Pharmaceuticals, Inc.	68180-568